

HAPC, Inc.
Form 10-Q/A
February 14, 2007
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

X **Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2006.**

or

.. **Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.**

Commission File Number: 000-51902

HAPC, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction of

20-3341405
(I.R.S. Employer Identification No.)

Incorporation or Organization)

350 Madison Avenue, New York, New York, 10017

(Address of Principal Executive Offices including Zip Code)

(212) 418-5070

(Registrant's Telephone Number, Include Area Code)

Edgar Filing: HAPC, Inc. - Form 10-Q/A

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act (check one).

Large Accelerated Filer Accelerated Filer Non-Accelerated Filer

Indicated by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 20, 2006, 21,041,918 shares of the registrant's common stock, par value \$0.0001 per share, were outstanding.

Table of Contents

HAPC, INC.

Explanatory Note

As discussed in Note 4 to the condensed consolidated financial statements included herein, HAPC, INC. (the Company) has restated in this Quarterly Report on Form 10-Q/A (the Form 10-Q/A) the Condensed Consolidated Financial Statements as of September 30, 2006 and for the three and nine months ended September 30, 2006, the period from August 15, 2005 (inception) to September 30, 2006 and the period January 1, 2006 to September 30, 2006 included in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2006 originally filed with the United States Securities and Exchange Commission (the SEC) on November 14, 2006 (the Form 10-Q).

On February 14, 2007, the management of the Company, after discussion with the Company's Audit Committee, determined that it was necessary for the Company to restate the Company's unaudited interim financial statements as of and for the three and nine months ended September 30, 2006 previously filed with the SEC on November 14, 2006 included in the Form 10-Q.

The Company's Condensed Consolidated Financial Statements referenced above have been restated to reflect gains and losses related to the warrants to purchase common stock associated with the units sold in connection with the Company's initial public offering in April 2006 and the partial exercise of the underwriter's over allotment option in May 2006. The Company had previously classified the value of these warrants to purchase common stock as equity. Subsequent to filing the Company's Form 10-Q, management determined that these warrants should have been classified as liabilities and, therefore, the fair value of each warrant must be recorded as a liability on the Company's balance sheet. Subsequent changes in the fair values of these warrants results in adjustments to the amount of the recorded liability, and the corresponding gain or loss recorded in the Company's statement of operations.

Additionally, the Company's statement of cash flows for the period from August 15, 2005 (inception) to September 30, 2006 includes mathematical corrections in the adjustments column to correct the as previously reported column in the Form 10-Q. The net loss adjustment includes \$385,694, which is a mathematical correction, and the warrant liability adjustment of \$9,450,140. The net cash used in investing activities line item includes a \$1,000,000 adjustment to correct a mathematical error and the proceeds from public offering line item included in cash flows from financing includes a \$100,000 adjustment to correct a mathematical error.

All the information in this Form 10-Q/A is as of November 14, 2006, the date the Company originally filed its Form 10-Q with the SEC, and does not reflect any subsequent information or events other than the restatement discussed in Note 4 to the Condensed Consolidated Financial Statements appearing in this Form 10-Q/A. For the convenience of the reader, this Form 10-Q/A sets forth the originally filed Form 10-Q in its entirety. However, the following items have been amended solely as a result of, and to reflect, the restatement, and no other information in the Form 10-Q/A is amended hereby as a result of the restatement:

Part I, Item 1, Financial Statements

Part I, Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations

Part I, Item 4, Controls and Procedures

Part II, Item 6, Exhibits

The Company is including currently dated Sarbanes-Oxley Act Section 302 and Section 906 certifications of the Chief Executive Officer and Chief Financial Officer that are attached to this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2.

Table of Contents

HAPC, INC. AND SUBSIDIARY

Index to Form 10-Q/A

| | PAGE |
|--|-------------|
| <u>PART I - FINANCIAL INFORMATION</u> | |
| Item 1. <u>Financial Statements:</u> | |
| <u>Condensed Consolidated Balance Sheets as of September 30, 2006 (Restated) and December 31, 2005</u> | 1-2 |
| <u>Condensed Consolidated Statements of Operations for the three months ended September 30, 2006 (Restated), the nine months ended September 30, 2006 (Restated), the period from August 15, 2005 (inception) to September 30, 2005 and for the period from August 15, 2005 (inception) to September 30, 2006 (Restated)</u> | 3 |
| <u>Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the period August 15, 2005 (inception) to December 31, 2005 and the period January 1, 2006 to September 30, 2006 (Restated)</u> | 4-5 |
| <u>Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2006 (Restated), for the period from August 15, 2005 (inception) to September 30, 2005 and for the period from August 15, 2005 (inception) to September 30, 2006 (Restated)</u> | 6-7 |
| <u>Notes to Condensed Consolidated Financial Statements</u> | 8-23 |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 24 |
| Item 4. <u>Controls and Procedures</u> | 27 |
| <u>PART II - OTHER INFORMATION</u> | |
| Item 6. <u>Exhibits</u> | 29 |
| <u>Signatures</u> | |

Table of Contents**PART I - FINANCIAL INFORMATION****Item 1. Financial Statements****HAPC, INC. AND SUBSIDIARY****(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)**

(a corporation in the development stage)

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

| | September 30, 2006 (Restated, see Note 4) | December 31, 2005 |
|--|--|----------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 609,232 | \$ 13,590 |
| Investments held in trust | 97,625,231 | |
| Prepaid expenses | 349,400 | |
| Deferred offering costs | | 165,088 |
| Deferred acquisition costs | 385,694 | |
| Total assets | \$ 98,969,557 | \$ 178,678 |
| LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) | | |
| Current Liabilities: | | |
| Accrued expenses | \$ 15,000 | \$ 93,954 |
| Stockholder advance | 100 | 100 |
| Notes payable | | 85,000 |
| Deferred underwriting fees | 5,468,000 | |
| Warrant liabilities | 10,462,656 | |
| Total Liabilities | 15,945,756 | 179,054 |
| COMMITMENTS | | |
| Common stock subject to possible conversion 3,373,363 and 0 shares, respectively at conversion value | 19,515,284 | |
| Stockholders Equity (Deficit) | | |
| Preferred stock, \$.0001 par value; authorized 1,000,000 shares; none issued and outstanding | | |
| Common stock, \$.0001 par value; authorized 200,000,000 shares; issued 21,041,918 and 4,166,667, respectively and outstanding 18,625,252 and 1,750,001, respectively | 2,104 | 417 |
| Additional paid-in capital | 71,559,128 | 23,990 |
| Deficit accumulated during the development stage | (8,052,715) | (24,783) |
| Total stockholders equity (deficit) | 63,508,517 | (376) |

| | | |
|--|----------------------|-------------------|
| Total liabilities and stockholders equity | \$ 98,969,557 | \$ 178,678 |
|--|----------------------|-------------------|

See accompanying notes to condensed consolidated financial statements.

Table of Contents**HAPC, INC. AND SUBSIDIARY****(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)**

(a corporation in the development stage)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

| | | | For the Period From | For the period from |
|---|--|---------------------------------------|--|--|
| | Three Months Ended September 30, | Nine Months Ended September 30, | August 15, 2005 (inception) to September 30, | August 15, 2005 (inception) to September 30, |
| | 2006 (Restated, see Note 4) | 2006 (Restated, see Note 4) | 2005 | 2006 (Restated, see Note 4) |
| Revenues | \$ | \$ | \$ | \$ |
| General and Administrative expenses | \$ 14,335,804 | \$ 18,895,774 | \$ 56 | \$ 18,920,257 |
| Loss from operations | (14,335,804) | (18,895,774) | (56) | (18,920,257) |
| Other Income (Expenses): | | | | |
| Interest income | 1,174,645 | 2,031,677 | | 2,031,677 |
| Interest expense | | (1,011) | | (1,311) |
| Gain (loss) on warrant liabilities | (337,505) | 9,450,140 | | 9,450,140 |
| | 837,140 | 11,480,806 | | 11,480,506 |
| Loss before provision for income taxes | (13,498,664) | (7,414,968) | (56) | (7,439,751) |
| Provision for income taxes | (421,071) | (612,964) | | (612,964) |
| Net loss | \$ (13,919,735) | \$ (8,027,932) | (56) | \$ (8,052,715) |
| Net loss per share | \$ (0.75) | \$ (.67) | \$ 0.00 | \$ (.89) |
| Weighted average shares outstanding basic and diluted | 18,625,252 | 11,988,221 | 1,507,092 | 9,040,132 |

See accompanying notes to condensed consolidated financial statements.

Table of Contents**HAPC, INC. AND SUBSIDIARY****(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)**

(a corporation in the development stage)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)

For the period August 15, 2005 (inception) to December 31, 2005

and the period January 1, 2006 to September 30, 2006 (Unaudited)

| | Common Stock | | Deficit | | Treasury Stock | | Total Stockhold Equity |
|--|------------------|------------|---------------|-----------------|--------------------|----------|------------------------------|
| | Shares | Par Value | Paid-in | Accumulated | Shares | Amount | |
| | | \$0.0001 | Capital in | During the | | | |
| | | | Excess of | Development | | | |
| Balance at August 15, 2005 | | \$ | | \$ | | \$ | |
| Common stock issued September 13, 2005 | 4,166,667 | 417 | 24,583 | | | | 25,000 |
| Treasury stock purchased | | | | | (4,166,667) | (25,000) | (25,000) |
| Expense of treasury shares for services | | | (25,000) | | 1,750,001 | 25,000 | |
| Amortization of stock based compensation expense | | | 24,407 | | | | 24,407 |
| Loss | | | | (24,783) | | | (24,783) |
| Balance at December 31, 2005 | 4,166,667 | 417 | 23,990 | (24,783) | (2,416,666) | | (1,612,842) |
| Balance of common stock and Warrants | 16,875,251 | 1,687 | 101,249,819 | | | | 101,251,757 |
| Classification of proceeds allocated to warrants-derivatives liabilities (As Restated, see Note 4) | | | (19,912,796) | | | | (19,912,796) |
| Cash compensation | | | 13,049,996 | | | | 13,049,996 |
| Expenses of offering | | | (10,827,020) | | | | (10,827,020) |
| Cash charge related to sale of option | | | 1,966,666 | | | | 1,966,666 |
| Amortization of stock based compensation expense | | | 5,523,757 | | | | 5,523,757 |
| Proceeds subject to possible conversion of 3,373,363 shares | | | (19,515,284) | | | | (19,515,284) |
| Loss (As Restated, see Note 4) | | | | (8,027,932) | | | (8,027,932) |
| Balance at September 30, 2006 | | | | | | | |
| (As Restated, See Note 4) | 21,041,918 | \$ 2,104 | \$ 71,559,128 | \$ (8,052,715) | (2,416,666) | \$ | \$ 63,508,705 |

See accompanying notes to condensed consolidated financial statements.

Table of Contents**HAPC, INC. AND SUBSIDIARY**

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

| | | For the period from August 15, 2005 | For the period from August 15, 2005 |
|---|---|---|---|
| | Nine Months Ended September 30, 2006 (Restated, See Note 4) | (inception) to September 30, 2005 | (inception) to September 30, 2006 (Restated, See Note 4) |
| Cash flows from operating activities: | | | |
| Net loss | \$ (8,027,932) | \$ (56) | \$ (8,052,715) |
| Adjustment to reconcile net loss to net cash used in operating activities: | | | |
| Gain on warrant liabilities | (9,450,140) | | (9,450,140) |
| Interest income on investments held in trust | (2,017,243) | | (2,017,243) |
| Withdrawal from investments held in trust | 606,805 | | 606,805 |
| Amortization of stock based compensation | 5,523,757 | | 5,548,164 |
| Non-cash compensation satisfied by grant of stock | 13,049,996 | | 13,049,996 |
| Changes in assets and liabilities: | | | |
| Increase in prepaid expenses | (349,400) | | (349,400) |
| Decrease in deferred offering costs | 165,088 | | |
| Increase (decrease) in accrued expenses | (78,954) | | 15,000 |
| Net cash used in operating activities | (578,023) | (56) | (649,533) |
| Cash flows from investing activities: | | | |
| Purchase of investments held in trust | (96,214,793) | | (96,214,793) |
| Payment of deferred acquisition costs | (385,694) | | (385,694) |
| Net cash used in investing activities | (96,600,487) | | (96,600,487) |
| Cash flows from financing activities: | | | |
| Advance from initial stockholder | | 100 | 100 |
| Proceeds from note payable | | | 60,000 |
| Payment of notes payable | (85,000) | | (85,000) |
| Payment of offering costs | (3,392,354) | (12,000) | (3,392,354) |
| Proceeds from public offering | 81,736,222 | 25,000 | 81,761,222 |
| Proceeds from issuance of shares subject to possible conversion | 19,515,284 | | 19,515,284 |
| Net cash provided by financing activities | 97,774,152 | 13,100 | 97,859,252 |
| Net change in cash | 595,642 | 13,044 | 609,232 |

| | | | | |
|---|-----------|----------------|-----------|----------------|
| Cash, beginning of period | | 13,590 | | |
| Cash, end of period | \$ | 609,232 | \$ | 13,044 |
| | | | \$ | 609,232 |
| Supplemental Disclosures of Cash Flow Information: | | | | |
| Cash paid for interest | \$ | 1,011 | \$ | 1,011 |
| Cash paid for taxes | | 612,964 | | 612,964 |
| Schedule of Non-Cash Financing Transactions | | | | |
| Options issued to underwriter | \$ | 1,966,666 | \$ | 1,966,666 |
| Deferred underwriting fees | | 5,468,000 | | 5,468,000 |
| Issuance of note payable for treasury stock | | | | 25,000 |
| Warrant obligation in connection with sale of units in offering | | 19,912,796 | | 19,912,796 |

See accompanying notes to condensed consolidated financial statements

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

The information in this Form 10-Q/A Report includes the financial position of HAPC, Inc. and its consolidated subsidiary, Iceland Acquisition Subsidiary, Inc. (collectively, the Company) as of September 30, 2006 and the results of operations for the three and nine months ended September 30, 2006 and the period from August 15, 2005 (date of inception) to September 30, 2005 and 2006 and of cash flows for the nine months ended September 30, 2006 and the periods from August 15, 2005 (date of inception) to September 30, 2005 and 2006. The financial statements of all entities are consolidated and all significant intercompany accounts are eliminated upon consolidation.

The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

In the opinion of management, all adjustments (consisting only of normal recurring accruals) have been made that are necessary to present fairly the financial position of HAPC, Inc. (formerly Healthcare Acquisition Partners Corp.) (the Company) as of September 30, 2006 and the results of its operations and its cash flows for the nine months ended September 30, 2006 and 2005 and period from August 15, 2005 (inception) to September 30, 2006 in conformity with generally accepted accounting principles. Operating results for the interim period are not necessarily indicative of the results to be expected for the full year.

2. Nature of Operations and Summary of Significant Accounting Policies

The Company was incorporated in Delaware on August 15, 2005 as a blank check company whose objective is to acquire through a merger, capital stock exchange, asset acquisition or other similar business combination, one or more operating businesses primarily in the healthcare sector.

Substantially all activity through September 30, 2006 relates to the Company's formation and the initial public offering described below. The Company has selected December 31 as its fiscal year end. The registration statement for the Company's initial public offering (the Public Offering) was declared effective on April 11, 2006. The Company consummated the Public Offering on April 18, 2006 and received gross proceeds of \$100,000,000. Legal fees totaling \$497,000 and underwriting costs totaling \$2,600,000 have been paid from these proceeds. The Company's management has broad discretion with respect to the specific application of the net proceeds of the Public Offering (as described in Note 3), although substantially all of the net proceeds of the Public Offering are intended to be applied toward consummating a business combination with one or more operating businesses whose fair value is, either individually or collectively, at least 80% of the Company's net assets at the time of such acquisition (Business Combination).

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2. Nature of Operations and Summary of Significant Accounting Policies (Continued)

In evaluating a prospective target business, the Company will consider, among other factors, its financial condition and results of operations; growth potential; experience and skill of management; availability of additional personnel; capital requirements; competitive position; barriers to entry into other industries; stage of development of products, processes or services; degree of current or potential market acceptance of the products, processes or services; proprietary features and degree of intellectual property or other protection of the products, processes or services; the regulatory environment of the industry; and costs associated with effecting the Business Combination. These criteria are not intended to be exhaustive.

Any evaluation relating to the merits of a particular Business Combination will be based, to the extent relevant, on the above factors, as well as other considerations deemed relevant by the Company in effecting a Business Combination consistent with its business objective.

There are no assurances the Company will be able to successfully effect a Business Combination.

Of the proceeds of the Public Offering, \$96,214,793 was deposited and is being held in a trust account (Trust Account) and invested in a money market fund, fully collateralized by U.S. government securities until the earlier of (i) the consummation of the first Business Combination or (ii) the distribution of the Trust Account as described below. The amount in the Trust Account includes \$5,468,000 of contingent underwriting compensation (the Discount) which will be paid to the underwriters if a Business Combination is consummated, but which will be forfeited if public stockholders elect to have their shares redeemed for cash if a Business Combination is not consummated. Pro rata decreases in the Discount will occur if there is a Business Combination consummated but there are up to 19.99% dissenting share holders who elect to have their shares redeemed for cash. The remaining amount of the proceeds may be used to pay business, legal, accounting, due diligence on prospective acquisitions and continuing general and administrative expenses.

The Company, after signing a definitive agreement for the acquisition of a target business, will submit such transaction for stockholder approval. In the event that stockholders owning 20% or more of the shares sold in the Public Offering vote against the Business Combination and exercise their conversion rights described below, the Business Combination will not be consummated. The Company's stockholders prior to the Public Offering (the Initial Stockholders) have agreed to vote their 1,750,001 shares of common stock in accordance with the vote of the majority in interest of all other stockholders of the Company (Public Stockholders) with respect to any Business Combination. The Initial Stockholders have agreed not to acquire any additional shares of the registrant in connection with or following the Public Offering. After consummation of a Business Combination, these voting safeguards will no longer be applicable.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2. Nature of Operations and Summary of Significant Accounting Policies (Continued)

The Company's Amended and Restated Certificate of Incorporation provides for mandatory liquidation of the Company in the event that the Company does not consummate a Business Combination within 18 months from the date of the consummation of the Public Offering, or 24 months from the consummation of the Public Offering in the event that a definitive agreement to complete a Business Combination was executed but was not consummated within such 18 month period. In the event of liquidation, it is likely that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the initial public offering price per share in the Public Offering (assuming no value is attributed to the Warrants contained in the Units to be offered in the Public Offering discussed in Note 3).

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates

Cash and cash equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

Accounting for Warrants and Derivative Instruments

On April 18, 2006, the Company consummated its initial public offering of 16,666,667 units. On May 18, 2006, the Company sold 208,584 Units (the Overallotment Units) to FTN Midwest Securities Corp. pursuant to a partial exercise by FTN Midwest Securities Corp., the lead underwriter in the Company's initial public offering, of its overallotment option. The Overallotment Units were sold at the offering price of \$6.00 per Unit, less FTN Midwest Securities Corp.'s 7% underwriting discount. Each unit consists of one share of common stock and two redeemable common stock purchase warrants. Each warrant entitles the holder to purchase from the Company one share of its common stock at an exercise price of \$5.00.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2. Nature of Operations and Summary of Significant Accounting Policies (Continued)

In September 2000, the Emerging Issues Task Force issued EITF 00-19, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in, a Company's Own Stock, (EITF 00-19) which requires freestanding derivative contracts that are settled in a company's own stock, including common stock warrants, to be designated as equity instruments, assets or liabilities. Under the provisions of EITF 00-19, a contract designated as an asset or a liability must be carried at its fair value on a company's balance sheet, with any changes in fair value recorded in the company's results of operations. A contract designated as an equity instrument must be included within equity, and no fair value adjustments are required from period to period. In accordance with EITF 00-19, the 33,750,502 warrants issued to purchase stock are separately accounted for as liabilities. The fair value of these warrants is shown on the Company's balance sheet and the unrealized changes in the value of these warrants are shown in the Company's statement of operations as Gain (loss) on warrant liabilities. These warrants are freely traded on the

Over The Counter Bulletin Board. Consequently, the fair value of these warrants is estimated as the market price of the warrant at each period end. To the extent the market price increases or decreases, the Company's warrant liabilities will also increase or decrease, including the effect on the Company's statement of operations.

Income taxes

The Company uses the liability method for reporting income taxes, under which current and deferred tax liabilities and assets are recorded in accordance with enacted tax laws and rates. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Under the liability method, the amounts of deferred tax liabilities and assets at the end of each period are determined using the tax rate expected to be in effect when taxes are actually paid or recovered. Future tax benefits are recognized when it is more likely than not that such benefits will be realized.

The Company has a deferred tax benefit of \$5,872,498 related to the charge for the reserve of certain shares of its common stock currently held as treasury stock. The Company has established a reserve for the full amount of the benefit based on the uncertainty if the benefit will be fully utilized.

Recently issued accounting pronouncements

In June 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109 (FIN 48), which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax positions. A tax benefit from an uncertain position may be recognized only if it is more likely than not that the position is sustainable on its technical merits. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. The Company does not expect FIN 48 will have a material effect on its consolidated financial condition or results of operations.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2. Nature of Operations and Summary of Significant Accounting Policies (Continued)

In September 2006, the FASB issued FASB Statement No. 157 Fair Value Measurements which relates to the definition of fair value, the methods used to measure fair value, and the expanded disclosures about fair value measurements. The provisions of FASB No. 157 are effective for financial statements issued for fiscal years beginning after November 15, 2007. The Company does not expect this statement to have a material effect on its consolidated financial condition or results of operations upon adoption.

In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 108, Considering The Effects Of Prior Year Misstatements When Quantifying Misstatements In Current Year Financial Statements, which provides guidance regarding the process of quantifying financial statement misstatements for the purpose of materiality assessment. The provisions are effective for fiscal years ending on or after November 15, 2006. The Company does not expect this bulletin to have a material effect on its consolidated financial condition or results of operations upon adoption.

Share-based payment

Statement of Financial Accounting Standards No. 123 (R), Share-Based Payment, requires all entities to recognize compensation expense in an amount equal to the fair value of share based payments made to employees, among other requirements.

Accordingly, share based payments issued to officers, directors and vendors are measured at fair value and recognized as expense over the related vesting periods.

Cash concentration of credit risk

The Company maintains cash balances with financial institutions, which, at times, may exceed the Federal Deposit Insurance Corporation limit. The Company has not experienced any losses to date as a result of this policy, and management believes there is little risk of loss.

3. Initial Public Offering

On April 18, 2006, the Company sold 16,666,667 units (Units) to the public at a price of \$6.00 per unit. Each Unit consists of one share of the Company's common stock, \$.0001 par value, and two Redeemable Common Stock Purchase Warrants (Warrants). Each Warrant will entitle the holder to purchase from the Company one share of common stock at an exercise price of \$5.00 commencing on the later of the completion of a Business Combination or one year from the effective date of the Offering and expiring five years from the effective date of the Offering. The Company may call the Warrants for redemption in whole and not in part at a price of \$.01 per Warrant at any time after the Warrants become exercisable. They cannot be redeemed unless the Warrant holders receive written notice not less than 30 days prior to the redemption; and, if, and only if, the reported last sale price of the common stock equals or exceeds \$8.50 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the notice of redemption to Warrant holders. In connection with the Public Offering, the Company paid to FTN Midwest Securities Corp. an underwriting discount of 7% of the public offering price and a non-accountable expense allowance of 1% of the public offering price.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

3. Initial Public Offering (Continued)

In addition, on April 18, 2006, the Company issued to FTN Midwest Securities Corp., for \$100, an option to purchase up to a total of 833,333 units. The units issuable upon exercise of this option are identical to those offered in the Public Offering, except that each of the warrants underlying this option entitles the holder to purchase one share of our common stock at a price of \$6.25. This option is exercisable at \$7.50 per unit commencing on the later of the consummation of a Business Combination and one year from the date of the prospectus and expiring five years from the date of the prospectus. The option may only be exercised or converted by the option holder.

The warrants issuable upon exercise of the option will be exercisable only if at the time of exercise (i) a registration statement under the Securities Act of 1933, as amended (the Securities Act), with respect to the common stock underlying the warrants issuable upon exercise of the option is effective, or (ii) in the opinion of counsel to the Company or counsel to the option holder reasonably satisfactory to the Company, the exercise of the warrants is exempt from the registration requirements of the Securities Act and such securities are qualified for sale or exempt from qualification under applicable securities laws of the states or other jurisdictions in which the registered holders reside. The warrants may not be exercised by, or securities issued to, any registered holder in any state in which such exercise or issuance would be unlawful. The option holder is not entitled to receive a net cash settlement or other settlement in lieu of physical settlement if the common stock underlying the warrants, or securities underlying the option, as applicable, are not covered by an effective registration statement.

The sale of the option was accounted for as an equity transaction. Accordingly, there was no net impact on the Company's financial position or results of operations, except for the recording of the \$100 proceeds from the sale. The Company determined that the fair value of the option on the date of sale was \$2.36 per unit, or \$1,966,666 total, using an expected life of five years, volatility of 47% and a risk-free interest rate of 3.98%. Accordingly, this amount was recorded as an expense of the offering resulting in a charge directly to stockholders' equity.

The volatility calculation of 47% is based on the 180 day average volatility of a representative sample of forty-one (41) healthcare industry companies (the Sample Companies) with market capitalization under \$200 million. Because it does not have a trading history, the Company needed to estimate the potential volatility of its common stock price. The volatility will depend on a number of factors, which cannot be ascertained at this time.

The Company referred to the 180 day average volatility of the Sample Companies because Management believes that the average volatility of such companies is a reasonable benchmark to use in estimating the expected volatility of the Company's common stock post-business combination. Although an expected life of five years was taken into account for purposes of assigning a fair value to the options, if the Company does not consummate a business combination within the prescribed time period and liquidates, the options would become worthless.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

3. Initial Public Offering (Continued)

On May 18, 2006, the Company sold 208,584 Units (the Overallotment Units) to FTN Midwest Securities Corp. pursuant to a partial exercise by FTN Midwest Securities Corp. of its overallotment option. The Overallotment Units were sold at the offering price of \$6.00 per Unit, minus FTN Midwest Securities Corp. 's 7% underwriting discount.

4. Restatement of Previously Issued Financial Statements

In February 2007, the Company concluded that it was necessary to restate the Condensed Consolidated Financial Statements as of September 30, 2006 and for the three and nine months ended September 30, 2006, the period from August 15, 2005 (inception) to September 30, 2006, the period January 1, 2006 to September 30, 2006, to reflect gains and losses related to the classification of and accounting for the warrants to purchase common stock associated with the units sold at the initial public offering of the Company including the overallotment shares issued on May 18, 2006. The Company had previously classified the value of these warrants to purchase common stock as equity. Subsequent to filing the Company 's Form 10-Q, management determined that these warrants should have been classified as liabilities and, therefore, the fair value of each warrant must be recorded as a liability on the Company 's balance sheet. Subsequent changes in the fair value of these warrants results in adjustments to the amount of the recorded liabilities, and the corresponding gain or loss recorded in the Company 's statement of operations. The fair value of the Company 's 33,750,502 warrants outstanding at September 30, 2006 was \$10,462,656 or \$0.31 per warrant.

Additionally, the Company 's statement of cash flows for the period from August 15, 2005 (inception) to September 30, 2006 includes mathematical corrections in the adjustments column to correct the as previously reported column in the Form 10-Q. The net loss adjustment includes \$385,694, which is a mathematical correction, and the warrant liability adjustment of \$9,450,140. The net cash used in investing activities line item includes a \$1,000,000 adjustment to correct a mathematical error and the proceeds from public offering line item included in cash flows from financing includes a \$100,000 adjustment to correct a mathematical error.

The impact of the restatement in the Company 's Condensed Consolidated Financial Statements is summarized below.

Table of Contents**HAPC, INC. AND SUBSIDIARY**

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**4. Restatement of Previously Issued Financial Statements (Continued)****STATEMENTS OF OPERATIONS**

| | For the period from August 15, 2005 (date of inception) through September 30, 2006 | | |
|---|---|---------------------|-----------------------|
| | As Previously | | |
| | Reported | Adjustments | As Restated |
| General and Administrative expenses | \$ (18,920,257) | \$ | \$ (18,920,257) |
| Interest income | 2,031,677 | | 2,031,677 |
| Interest expense | (1,311) | | (1,311) |
| Gain on warrant liabilities | | 9,450,140 | 9,450,140 |
| Loss before provision for taxes | (16,889,891) | 9,450,140 | (7,439,751) |
| Provision for income taxes | 612,964 | | 612,964 |
| Net loss | \$ (17,502,855) | \$ 9,450,140 | \$ (8,052,715) |
| Weighted average shares outstanding - basic | 9,040,132 | | 9,040,132 |
| Net loss per share | \$ (1.94) | \$ 1.05 | \$ (0.89) |

| | For the three months ended September 30, 2006 | | |
|---|--|---------------------|------------------------|
| | As Previously | | |
| | Reported | Adjustments | As Restated |
| General and Administrative expenses | \$ (14,335,804) | \$ | \$ (14,335,804) |
| Interest income | 1,174,645 | | 1,174,645 |
| Interest expense | | | |
| Loss on warrant liabilities | | (337,505) | (337,505) |
| Loss before provision for taxes | (13,161,159) | (337,505) | (13,498,664) |
| Provision for income taxes | 421,071 | | 421,071 |
| Net loss | \$ (13,582,230) | \$ (337,505) | \$ (13,919,735) |
| Weighted average shares outstanding - basic | 18,625,252 | | 18,625,252 |
| Net loss per share | \$ (0.73) | \$ (0.02) | \$ (0.75) |

Table of Contents**HAPC, INC. AND SUBSIDIARY****(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)**

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**4. Restatement of Previously Issued Financial Statements (Continued)**

| | For the nine months ended September 30, 2006 As Previously | | |
|---|---|---------------------|-----------------------|
| | Reported | Adjustments | As Restated |
| General and Administrative expenses | \$ (18,895,774) | \$ | \$ (18,895,774) |
| Interest income | 2,031,677 | | 2,031,677 |
| Interest expense | (1,011) | | (1,011) |
| Gain on warrant liabilities | | 9,450,140 | 9,450,140 |
| Loss before provision for taxes | (16,865,108) | 9,450,140 | (7,414,968) |
| Provision for income taxes | 612,964 | | 612,964 |
| Net loss | \$ (17,478,072) | \$ 9,450,140 | \$ (8,027,932) |
| Weighted average shares outstanding - basic | 11,988,221 | | 11,988,221 |
| Net loss per share | \$ (1.46) | \$ 0.79 | \$ (0.67) |

Table of Contents**HAPC, INC. AND SUBSIDIARY**

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**4. Restatement of Previously Issued Financial Statements (Continued)****BALANCE SHEET**

| | September 30, | | September 30, |
|--|----------------------|---------------------|----------------------|
| | 2006 | | 2006 |
| | As Previously | | 2006 |
| | Reported | Adjustments | As Restated |
| ASSETS | | | |
| Current assets: | | | |
| Cash and cash equivalents | \$ 609,232 | \$ | \$ 609,232 |
| Cash held in trust account | 97,625,231 | | 97,625,231 |
| Prepaid expenses | 349,400 | | 349,400 |
| Deferred acquisition costs | 385,694 | | 385,694 |
| Total assets | \$ 98,969,557 | | \$ 98,969,557 |
| LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) | | | |
| Current Liabilities: | | | |
| Accrued expenses | \$ 15,000 | \$ | \$ 15,000 |
| Stockholder advance | 100 | | 100 |
| Deferred underwriting fees | 5,468,000 | | 5,468,000 |
| Warrant liabilities | | 10,462,656 | 10,462,656 |
| Total Liabilities | 5,483,100 | 10,462,656 | 15,945,756 |
| COMMITMENTS | | | |
| Common Stock subject to conversion 3,373,363 and 0 shares, respectively, at conversion value | 19,515,284 | | 19,515,284 |
| Stockholders Equity (Deficit) | | | |
| Preferred stock, \$.0001 par value; authorized 1,000,000 shares; none issued and outstanding | | | |
| Common stock, \$.0001 par value; authorized 200,000,000 shares; issued 21,041,918 and 4,166,667, respectively and outstanding 18,625,252 and 1,750,001, respectively | 2,104 | | 2,104 |
| Additional paid-in capital | 91,471,924 | (19,912,796) | 71,559,128 |
| Retained Earnings (Deficit accumulated) during the development stage | (17,502,855) | 9,450,140 | (8,052,715) |
| Total stockholders equity (deficit) | 73,971,173 | (10,462,656) | 63,508,517 |
| Total liabilities and stockholders equity | \$ 98,969,557 | \$ | \$ 98,969,557 |

STATEMENT OF STOCKHOLDERS EQUITY

| | Common Stock | | Paid-in Capital in Excess of Par | Deficit Accumulated During the Development Stage | Treasury Stock | | Total Stockholders Equity |
|--|-------------------|------------------------------------|--|--|--------------------|-----------|---------------------------------|
| | Shares | Par Value \$0.0001 Amount | | | Shares | Amount | |
| Balance at September 30, 2006 (as previously reported) | 21,041,918 | \$ 2,104 | \$ 91,471,924 | \$ (17,502,855) | (2,416,666) | \$ | \$ 73,971,173 |
| Restatement adjustments | | | (19,912,796) | 9,450,140 | | | (10,462,656) |
| Balances at September 30, 2006 (as restated) | 21,041,918 | \$ 2,104 | \$ 71,559,128 | \$ (8,052,715) | (2,416,666) | \$ | \$ 63,508,517 |

Table of Contents**STATEMENTS OF CASH FLOWS**

| | Nine Months Ended September 30, 2006 As previously reported | Nine Months Ended September 30, 2006 Adjustments | Nine Months Ended September 30, 2006 As Restated |
|---|--|--|--|
| Cash flows from operating activities: | | | |
| Net loss | \$ (17,478,072) | \$ 9,450,140 | \$ (8,027,932) |
| Adjustment to reconcile net loss to net cash used in operating activities: | | | |
| Gain on warrant liabilities | | (9,450,140) | (9,450,140) |
| Changes in assets and liabilities: | | | |
| Interest income on investments held in trust | (2,017,243) | | (2,017,243) |
| Withdrawal from investments held in trust | 606,805 | | 606,805 |
| Amortization of stock based compensation | 5,523,757 | | 5,523,757 |
| Non-cash compensation satisfied by grant of stock | 13,049,996 | | 13,049,996 |
| Increase in prepaid expenses | (349,400) | | (349,400) |
| Decrease in deferred offering costs | 165,088 | | 165,088 |
| Increase (decrease) in accrued expenses | (78,954) | | (78,954) |
| Net cash used in operating activities | (578,023) | | (578,023) |
| Cash flows from investing activities: | | | |
| Purchase of investments held in trust | (96,214,793) | | (96,214,793) |
| Payment of deferred acquisition costs | (385,694) | | (385,694) |
| Net cash used in investing activities | (96,600,487) | | (96,600,487) |
| Cash flows from financing activities: | | | |
| Advance from initial stockholder | | | |
| Proceeds from note payable | | | |
| Payment of notes payable | (85,000) | | (85,000) |
| Payment of offering costs | (3,392,354) | | (3,392,354) |
| Proceeds from public offering | 81,736,222 | | 81,736,222 |
| Proceeds from issuance of shares subject to possible conversion | 19,515,284 | | 19,515,284 |
| Net cash provided by financing activities | 97,774,152 | | 97,774,152 |
| Net change in cash | 595,642 | | 595,642 |
| Cash, beginning of period | 13,590 | | 13,590 |
| Cash, end of period | \$ 609,232 | \$ | \$ 609,232 |
| Supplemental Disclosures of Cash Flow Information: | | | |
| Cash paid for interest | \$ 1,011 | \$ | \$ 1,011 |
| Cash paid for taxes | 612,964 | | 612,964 |
| Schedule of Non-Cash Financing Transactions | | | |
| Options issued to underwriter | \$ 1,966,666 | \$ | \$ 1,966,666 |
| Deferred underwriting fees | 5,468,000 | | 5,468,000 |
| Issuance of note payable for treasury stock | | | |
| Warrant obligation in connection with sale of units in offering | | 19,912,796 | 19,912,796 |

Table of Contents

| | For the period from August 15, 2005 (inception) to September 30, 2006 As previously reported | For the period from August 15, 2005 (inception) to September 30, 2006 Adjustments | For the period from August 15, 2005 (inception) to September 30, 2006 As restated |
|---|---|--|---|
| Cash flows from operating activities: | | | |
| Net loss | \$ (17,888,549) | \$ 9,835,834 | \$ (8,052,715) |
| Adjustment to reconcile net loss to net cash used in operating activities: | | | |
| Gain on warrant liabilities | | (9,450,140) | (9,450,140) |
| Changes in assets and liabilities: | | | |
| Interest income on investments held in trust | (2,017,243) | | (2,017,243) |
| Withdrawal from investments held in trust | 606,805 | | 606,805 |
| Amortization of stock based compensation | 5,548,164 | | 5,548,164 |
| Non-cash compensation satisfied by grant of stock | 13,049,996 | | 13,049,996 |
| Increase in prepaid expenses | (349,400) | | (349,400) |
| Increase (decrease) in accrued expenses | 15,000 | | 15,000 |
| Net cash provided by (used in) operating activities | (1,035,227) | 385,694 | (649,533) |
| Cash flows from investing activities: | | | |
| Purchase of investments held in trust | (96,214,793) | | (96,214,793) |
| Payment of deferred acquisition costs | (385,694) | | (385,694) |
| Net cash used in investing activities | (95,600,487) | (1,000,000) | (96,600,487) |
| Cash flows from financing activities: | | | |
| Advance from initial stockholder | 100 | | 100 |
| Proceeds from note payable | 60,000 | | 60,000 |
| Payment of notes payable | (85,000) | | (85,000) |
| Payment of offering costs | (3,392,354) | | (3,392,354) |
| Proceeds from public offering | 81,861,222 | (100,000) | 81,761,222 |
| Proceeds from issuance of shares subject to possible conversion | 19,515,284 | | 19,515,284 |
| Net cash provided by financing activities | 97,859,252 | | 97,859,252 |
| Net change in cash | 609,232 | | 609,232 |
| Cash, beginning of period | | | |
| Cash, end of period | \$ 609,232 | \$ | \$ 609,232 |
| Supplemental Disclosures of Cash Flow Information: | | | |
| Cash paid for interest | \$ 1,011 | \$ | \$ 1,011 |
| Cash paid for taxes | 612,964 | | 612,964 |
| Schedule of Non-Cash Financing Transactions | | | |
| Options issued to underwriter | \$ 1,966,666 | \$ | \$ 1,966,666 |
| Deferred underwriting fees | 5,468,000 | | 5,468,000 |
| Issuance of note payable for treasury stock | 25,000 | | 25,000 |
| Warrant obligation in connection with sale of units in offering | | 19,912,796 | 19,912,796 |

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

5. Investments Held In Trust

Investments held in trust at September 30, 2006, consist of a United States Treasury money market account with a carrying value of \$97,625,231. The fair value of the investments approximate the carrying value. There were no investments held in trust as of December 31, 2005.

6. Notes Payable

On September 28, 2005, the Company issued a \$60,000 unsecured promissory note to Healthcare Acquisition Holdings, LLC (Holdings), a company owned by certain directors of the Company. The note bears interest at a rate of 3% per annum and is payable on the earlier of September 28, 2006 or the date the Company consummates a Public Offering.

On December 30, 2005, the Company issued an \$25,000 unsecured promissory note, at an interest rate of 3% per annum to Holdings, to repurchase the 4,166,667 common shares that Holdings received upon formation of the Company. At September 30, 2006, 2,416,666 shares were included in the Treasury shares of the Company.

Due to the short-term nature of the notes, the fair values of the notes approximate the carrying values. Both notes were re-paid in full in May 2006 and are no longer outstanding.

Interest expense for the nine months ended September 30, 2006 and 2005 was \$1,011 and \$0, respectively.

7. Related Party Transactions

The Company was initially funded by Holdings which is owned by certain directors of the Company. Cash was received from the issuance of two unsecured promissory notes (see footnote 6). The proceeds were used as working capital until the Company was able to consummate its Public Offering. Both notes were repaid in full in May 2006.

Two of the Company's directors are employees of FTN Midwest Securities Corp. FTN Midwest Securities Corp., who was the underwriter in the Company's initial public offering, received an underwriting discount of 7%, a non-accountable expense allowance of 1% and an option to purchase 833,333 shares for a fee of \$100. The Company reserved for these directors 2,416,666 shares of its common stock held in treasury.

The Company currently utilizes and will continue to utilize certain administrative, technological and secretarial services, as well as certain limited office space provided by FTN Midwest Securities Corp. until the consummation of a Business Combination by the Company. The Company has agreed to pay \$1 per year for such services commencing on the effective date of the Public Offering and continuing monthly thereafter.

Refer to footnote 10 for discussion of the Termination and Break Up Fee and the related guaranty.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

8. Commitments

The Company's chief executive officer receives annual compensation of \$50,000 for serving as an officer and \$50,000 for serving as a director. The Company's chief financial officer receives annual compensation of \$50,000 and the Company's independent directors each receive annual compensation of \$50,000.

The Company has entered into agreements with FTN Midwest Securities Corp. and certain officers and directors whereby each of them has agreed to present the Company, for its consideration, with any opportunity to acquire all or substantially all of the outstanding equity securities of, or otherwise acquire a controlling equity interest in, an operating business in the healthcare, or a healthcare-related, sector, provided that they are under no obligation to present the Company with any opportunity involving a business in the healthcare, or a healthcare-related, sector seeking a strategic combination with another operating business in the healthcare, or a healthcare-related, sector.

Certain of our officers and directors have committed to purchase \$1,000,000 of the Company's warrants from the Company in a private placement at a price of \$.70 per warrant upon the filing of the preliminary proxy statement soliciting stockholder approval for the Stock Purchase Agreement discussed in Note 10. Such officers and directors have agreed not to sell or transfer the warrants until after a business combination.

The Company currently utilizes and will continue to utilize certain administrative, technological and secretarial services, as well as certain limited office space provided by FTN Midwest Securities Corp. until the consummation of a Business Combination by the Company. The Company has agreed to pay \$1 per year for such services commencing on the effective date of the Public Offering and continuing monthly thereafter.

Our initial stockholders are entitled to demand that we register the resale of their shares of common stock at any time six months following the consummation of the acquisition, pursuant to the terms of their respective lock-up agreements.

The Company has agreed to reimburse our initial stockholders for (a) any income tax liability incurred by our initial stockholders as a result of the award of their shares and/or the vesting of such shares (other than tax liability due as a result of their sale of such shares) and (b) all reasonable out-of-pocket expenses incurred by the initial stockholders in connection with their activities on the Company's behalf.

Table of Contents**HAPC, INC. AND SUBSIDIARY****(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)**

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**9. Common and Preferred Stock**

Effective December 30, 2005, Holdings sold the 4,166,667 common shares that it had received upon formation of the Company back to the Company. The shares were purchased for a \$25,000 note payable. Simultaneously, the Company transferred 1,750,001 of these common shares to certain members of its management team resulting in compensation of \$8,435,005 to them, computed at \$4.82 per share, which will be charged to expense ratably over the forfeiture period. Of this amount, \$24,407 and \$5,523,757 was charged to expense for the periods ended December 31, 2005 and September 30, 2006, respectively. The Company will recognize the remaining \$2,886,841 of compensation as an expense ratably over the forfeiture period of the shares. Each individual receiving shares has agreed to forfeit a portion of their shares if they cease to be an officer or director prior to the following dates (other than as a result of (i) disability, (ii) death, (iii) removal by the Company without cause, or (iv) resignation for Good Reason, the portion of the shares to be forfeited is as follows):

| Termination of Services Prior To: | Shares Forfeited |
|--|-------------------------|
| September 30, 2006 | 100% |
| December 31, 2006 | 75% |
| September 30, 2007 | 50% |
| December 31, 2007 | 25% |

The 2,416,666 shares of our common stock transferred back to us and not transferred to members of the Company's management team on December 30, 2005 are being held as treasury shares and reserved for transfer by the Company's board of directors to present or future officers, directors or employees.

On July 24, 2006, the Company reserved for grant to two of the Company's Directors 2,416,666 shares of the Company's common stock. These shares were originally held as treasury shares and reserved for transfer to present or future officers, directors or employees.

The grants may not be transferred prior to the date that is the later of six months after the completion of a business combination or April 11, 2007 (being the first anniversary of the Company's initial Public Offering).

As a result of the above, the Company took a charge of \$13,049,996 in its quarter ended September 30, 2006 which is based upon the number of shares reserved (2,416,666) at the July 24, 2006 closing stock price of \$5.40 per share.

The Company is authorized to issue 1,000,000 shares of preferred stock with such designations, voting and other rights and preferences as may be determined from time to time by the Board of Directors.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

10. Stock Purchase Agreement

Entry into a Material Definitive Agreement

On September 29, 2006, HAPC, Inc., a Delaware corporation (HAPC) entered into a Stock Purchase Agreement (the Stock Purchase Agreement) with I-Flow Corporation, a Delaware corporation (I-Flow), Iceland Acquisition Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of HAPC (Acquisition Sub) and InfuSystem, Inc., a California corporation and wholly-owned subsidiary of I-Flow (InfuSystem). Pursuant to the terms of the Stock Purchase Agreement, Acquisition Sub will purchase all of the issued and outstanding capital stock of InfuSystem. Concurrently with the acquisition, Acquisition Sub will merge with and into InfuSystem. After the merger, Acquisition Sub will cease to exist as an independent entity and InfuSystem, as the surviving corporation, will continue its corporate existence under the laws of the State of California. The name of the surviving corporation will be InfuSystem, Inc.

HAPC 's amended and restated certificate of incorporation (the Certificate of Incorporation) requires that the acquisition must be approved by the holders of a majority of the shares of HAPC common stock sold in HAPC 's Public Offering. The acquisition cannot be completed if holders of 20% or more of the shares of HAPC common stock sold in the Public Offering vote against the acquisition and, as permitted by the Certificate of Incorporation, demand that their shares be converted (the Conversion Rights) into the right to receive a pro rata portion of the net proceeds of the Public Offering held in a trust account established for this purpose at the time of the Public Offering (the approval of the majority of the shares cast together with the exercise of the Conversion Rights by less than 20% of the HAPC common stock issued in the Public Offering, HAPC Stockholder Approval). If the holders of less than 20% of the shares of HAPC common stock exercise their Conversion Rights and the transaction closes, such holders will receive their pro rata share of the trust proceeds.

Purchase Price

In consideration for the acquisition of all of the issued and outstanding shares of capital stock of InfuSystem, HAPC or Acquisition Sub will pay to I-Flow a purchase price of \$140,000,000, subject to certain working capital adjustments as set forth in the Stock Purchase Agreement. The purchase price will be paid by HAPC or Acquisition Sub in cash or a combination of (i) a secured promissory note (the Promissory Note) payable to I-Flow in a principal amount equal to \$55,000,000 plus the amount actually paid to HAPC 's stockholders who exercise their Conversion Rights but not to exceed \$75,000,000 (the Maximum Amount) and (ii) an amount of cash purchase price equal to \$65,000,000 plus the difference between the Maximum Amount and the actual principal amount of the Promissory Note. In connection with I-Flow 's commitment to accept the Promissory Note, a \$100,000 delivery fee is payable by HAPC to I-Flow by October 4, 2006 and a Ticking Fee (between 0.50% and 1.0% per annum of the Maximum Amount) is payable from September 29, 2006 until the earlier of the closing under the Stock Purchase Agreement, termination of the Stock Purchase Agreement or HAPC 's notice that, because alternative financing has been secured, the Promissory Note to I-Flow will no longer be required. On October 4, 2006, the Company paid \$100,000 to I-Flow representing the delivery fee.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

10. Stock Purchase Agreement (Continued)

Representations, Warranties and Covenants

The Stock Purchase Agreement contains representations and warranties of each of HAPC, I-Flow, Acquisition Sub and InfuSystem, as applicable, relating to, among other matters, (i) corporate organization and similar corporate matters, (ii) title to stock, (iii) capitalization, (iv) the authorization, performance and enforceability of the Stock Purchase Agreement, (v) taxes, (vi) financial statements and the absence of undisclosed liabilities, (vii) material contracts, (viii) absence of certain changes, (ix) compliance with applicable laws, (x) absence of litigation, (xi) insurance, (xii) consents, (xiii) licenses and permits, (xiv) validity of leases, (xv) title to assets, (xvi) employer and employee benefit matters, (xvii) environmental matters and (xviii) intellectual property matters.

InfuSystem has agreed to continue to operate its business in the ordinary course prior to the closing of the transactions contemplated by the Stock Purchase Agreement and each of the parties has agreed (i) not to take any action to cause its representations and warranties to become untrue and (ii) to use all commercially reasonable efforts to consummate the transactions contemplated by the Stock Purchase Agreement in accordance with the terms set forth therein. Each party has also agreed to maintain the confidentiality of the other's proprietary information.

Indemnification

Under the Stock Purchase Agreement, each of HAPC and I-Flow have agreed to indemnify the other and its affiliates, subject to certain limitations, against certain losses arising from, among other matters, such party's breach of the Stock Purchase Agreement.

Termination and Break Up Fee

In the event that the Stock Purchase Agreement is terminated (i) because of HAPC's failure to obtain HAPC Stockholder Approval by April 30, 2007 for any reason or (ii) because HAPC or Acquisition Sub is unwilling or unable to consummate the transactions contemplated by the Stock Purchase Agreement notwithstanding the fact that all conditions precedent to the Stock Purchase Agreement to be satisfied by I-Flow and InfuSystem (and the receipt of HAPC Stockholder Approval) have been satisfied or are capable of fulfillment, HAPC must pay I-Flow a break up fee. In the event that I-Flow terminates the Stock Purchase Agreement after April 30, 2007 and the break up fee is payable for the sole reason that HAPC has not held the stockholder meeting seeking HAPC Stockholder Approval by April 30, 2007, the break up fee will be \$1,000,000. In all other cases where a break up fee is payable, the amount will be \$3,000,000.

Table of Contents

HAPC, INC. AND SUBSIDIARY

(formerly HEALTHCARE ACQUISITION PARTNERS CORP.)

(a corporation in the development stage)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

10. Stock Purchase Agreement (Continued)

Payment of the break up fee has been guaranteed to I-Flow by Messrs. Sean D. McDevitt and Philip B. Harris (the Guarantors) pursuant to a Continuing Guaranty provided by the Guarantors in favor of I-Flow and delivered concurrently with the execution of the Stock Purchase Agreement. Pursuant to the terms of a Guarantee Fee and Reimbursement Agreement entered into by HAPC and the Guarantors on September 29, 2006, HAPC has agreed to pay the Guarantors a fee of \$100,000 upon delivery of the Continuing Guaranty and \$300,000 upon closing of the transactions contemplated by, or the termination of, the Stock Purchase Agreement. HAPC has also agreed to reimburse the Guarantors for any payments actually made by them in connection with the Continuing Guaranty. Messrs. McDevitt and Harris have delivered to I-Flow a \$3,000,000 letter of credit issued by JPMorgan for the benefit of I-Flow which I-Flow may draw upon in the event that the break up fees are not paid when due and payable

Table of Contents

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements**

Management's Discussion and Analysis of Financial Condition and Results of Operations has been revised for the effects of the restatement discussed in Note 4 to the Condensed Consolidated Financial Statements.

This Quarterly Report on Form 10-Q/A includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as *may*, *should*, *could*, *would*, *expect*, *plan*, *anticipate*, *believe*, *estimate*, the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission filings. The following discussion should be read in conjunction with our Condensed Consolidated Financial Statements and related Notes thereto included elsewhere in this Form 10-Q/A and the Audited Financials included in our other Security and Exchange filings.

Critical Accounting Policies and Estimates

Management's discussion and analysis addresses the Company's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Management believes the following critical accounting policies involve its more significant judgments and estimates used in the preparation of the financial statements. On an ongoing basis, management evaluates its estimates and judgment including those related to intangible assets, income taxes, share-based payment and contingencies.

Share-Based Payments

Management uses certain assumptions to determine the value of share-based payments based on fair value. These can include, as appropriate, relevant modeling techniques such as the Black-Scholes model and analyses of the valuation of various derivative securities of other comparable publicly traded companies.

Valuation of Warrants

Fair values for traded securities and derivatives are based on quoted market prices. Where market prices are not readily available, as in the case of the Company's warrants as of the date of issuance, fair values are determined using methods requiring judgment and estimates. Before the warrants were publicly traded, the Company allocated the unit price between the share of common and the warrants issued based upon relative fair value determined, among other things, by reference to comparative companies. The warrants included in the units sold in the Company's Public Offering and the underwriter's over allotment option began to be publicly traded on the Over the Counter Bulletin Board on June 15, 2006, and consequently the market value of the warrants is reflected as the fair value of the warrants at each period end. To the extent that the market prices of the Company's warrants increase or decrease, the Company's derivative liabilities will also increase or decrease with a corresponding impact on its statement of operations.

Table of Contents

Overview

We were organized as a Delaware corporation on August 15, 2005, to serve as a vehicle to acquire, through a merger, capital stock exchange, asset acquisition or other similar business combination, one or more operating businesses primarily in the healthcare sector. Our initial business combination must be with a target business or businesses whose fair market value is at least equal to 80% of net assets at the time of such acquisition. We intend to utilize cash derived from the proceeds of our initial public offering, our capital stock, debt or a combination of cash, capital stock and debt, in effecting a business combination.

On September 29, 2006, the Company entered into a Material Definitive Agreement with InfuSystem, Inc. who, if the Business Combination will be consummated, will be the surviving corporation and continue its corporate existence under the laws of the State of California. An in depth discussion of the possible merger can be found under footnote 10.

Results of Operations for the Three and Nine months Ended September 30, 2006 with Prior Year Period

During the three months ended September 30, 2006, we had not yet consummated a business combination with one or more operating businesses, however we signed a Material Definitive Agreement (see footnote 10) and incurred non-cash expenses of \$1,142,240 and \$13,049,996, which represented the amortization of stock based compensation and the value of 2,416,666 shares granted to two of the Company's Directors, respectively, as well as a non-cash loss on warrant liabilities of \$337,505. The balance of expenses were offset by interest income of \$1,174,645, resulting in a net loss of \$13,919,735 for the three months ended September 30, 2006.

During the nine months ended September 30, 2006, in addition to incurring \$5,523,757 and \$13,049,996 of non-cash expenses, we completed our initial public offering. The net loss of \$8,027,932 for the nine months ended September 30, 2006 primarily consisted of non-cash expenses, representing amortization of compensation costs and the value of granted stock. These expenses were offset by interest income totaling \$2,031,677, earned on proceeds from the Public Offering, and a non-cash gain of \$9,450,140 on warrant liabilities.

For the period of the prior year which comprised August 15, 2005 (date of inception) to September 30, 2005, the Company had substantially no operations.

Liquidity and Capital Resources

For the nine months ended September 30, 2006, the Company experienced positive cash flow and financed its operations primarily from cash generated from its issuance of stock at its consummated initial Public Offering, discussed below in further detail. As of September 30, 2006, the Company had \$609,232 of cash and cash equivalents, an increase of \$595,642 from the \$13,590, at December 31, 2005, which relates primarily to interest income.

Net cash used by operating activities for the nine months ended September 30, 2006 was \$578,023, which included the Company's net loss of \$8,027,932, an increase in prepaid expenses of \$349,400, a decrease in accrued expenses of \$78,954, and a non-cash gain on warrant liabilities of \$9,450,140. This was offset by non-cash charges of \$5,523,757 and \$13,049,996, representing stock based compensation and non-cash compensation satisfied by grant of stock, respectively.

Table of Contents

Net cash used in investing activities for the nine months ended September 30, 2006 amounted to \$96,600,487, the result of purchasing investments held in trust for \$96,214,793 and the payment of deferred acquisition costs totaling \$385,694. The investments held in trust are only to be utilized for the acquisition of a target business or the payment of income taxes.

Net cash provided by financing activities for the nine months ended September 30, 2006 was the result of proceeds of \$101,251,806 received from issuance of shares of stock, offset by payments of notes payable totaling \$85,000 and payment for costs associated with the Company's initial public offering amounting to \$3,392,354.

The Company entered into a Material Definitive Agreement, discussed in more detail in footnote 10. There can be no assurance that such transaction will be consummated. In the event that the proposed acquisition is not undertaken, it is likely that the Company will have insufficient time and resources to look for another suitable acquisition target and will most likely have to liquidate.

On April 18, 2006, we consummated our initial public offering (the "Public Offering") of 16,666,667 units sold to the public at a price of \$6.00 per unit. Each Unit consists of one share of the Company's common stock, \$.0001 par value, and two Redeemable Common Stock Purchase Warrants ("Warrants"). Each Warrant will entitle the holder to purchase from the Company one share of common stock at an exercise price of \$5.00 commencing on the later of the completion of a Business Combination or one year from the effective date of the Offering and expiring five years from the effective date of the Offering. The Company may call the Warrants for redemption in whole, but not in part, at a price of \$.01 per Warrant at any time after the Warrants become exercisable. They cannot be redeemed unless the Warrant holders receive written notice not less than 30 days prior to the redemption; and if, and only if, the reported last sale price of the common stock equals or exceeds \$8.50 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the notice of redemption to Warrant holders.

On May 18, 2006, we sold an additional 208,584 units (the "Overallotment") pursuant to a partial exercise by FTN Midwest Securities Corp. of its Overallotment option.

Net proceeds (including the Overallotment) after underwriting, legal, accounting, and printing costs amounted to approximately \$97,859,000 which includes a contingent underwriting fee of \$5,468,000. \$97,625,231 is being held in a Trust account. We will use substantially all of the net proceeds of the Public Offering to acquire a target business, including identifying and evaluating prospective acquisition candidates, selecting the target business, and structuring, negotiating and consummating the business combination.

We granted a purchase option to the representative of the underwriter at the closing of the Public Offering on April 18, 2006 to acquire 833,333 units for \$100. The units issuable upon exercise of this option are identical to those offered in the Public Offering, except that each of the warrants underlying this option entitles the holder to purchase one share of our common stock at a price of \$6.25. This option is exercisable at \$7.50 per unit commencing on the later of the consummation of a Business Combination and one year from the date of the prospectus and expiring five years from the date of the prospectus. The option may only be exercised or converted by the option holder.

The sale of the option was accounted for as an equity transaction. Accordingly, there was no net impact on the Company's financial position or results of operations, except for the recording of the \$100 proceeds from the sale. The Company has determined that the fair value of the option on the date of sale was \$2.36 per unit, or approximately \$1,966,666 total, using an expected life of five years, volatility of

Table of Contents

47% and a risk-free interest rate of 3.98%. Accordingly, this amount was recorded as an expense of the offering resulting in a charge directly to the stockholders' equity.

Off-Balance Sheet Arrangements

We do not have any material off-balance sheet arrangements.

Contractual Obligations

We do not have any material contractual obligations.

Item 4. Controls and Procedures Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure material information required to be disclosed in our reports that we file or submit under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with a company have been detected.

As of the end of the period covered by our Form 10-Q, we carried out an evaluation, under the supervision and with the participation of the Audit Committee and management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) of the Exchange Act. The Chief Executive Officer and Chief Financial Officer originally concluded that our disclosure controls and procedures were effective, at the reasonable assurance level. However, because of the material weakness discussed below, management has reconsidered, and contemporaneously concluded in connection with the filing of this 10-Q/A, that our disclosure controls and procedures were ineffective. A material weakness, as defined by the Public Company Accounting Oversight Board, is a significant deficiency, or a combination of significant deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. Management determined that a material weakness existed in the Company's financial closing and reporting process as of September 30, 2006. Specifically, the Company does not have sufficient resources with the appropriate expertise to adequately evaluate complex transactions entered into by the Company and determine the appropriate application of generally accepted accounting principles (GAAP). This material weakness resulted in the error in accounting for the effects of our warrants issued to purchase common stock.

Table of Contents

In light of the material weakness, we performed additional procedures to ensure that the condensed consolidated financial statements are prepared in accordance with GAAP. These procedures have included increased reliance upon outside accountants to review our condensed consolidated financial statements to ensure that they are prepared in accordance with GAAP. The outside accountants are not our external auditors. Accordingly, management believes that the financial statements included in this Form 10-Q/A fairly present in all material respects our financial condition, results of operation and cash flows for the periods presented.

Change in Internal Control

We are in the process of implementing improved procedures and controls designed to increase our ability to evaluate complex transactions and determine the appropriate application of GAAP. These include a review of the resources and personnel dedicated to the preparation of our financial statements. There were no material changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) under the Exchange Act that occurred during the quarter ended September 30, 2006, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. However, subsequently we have begun to take the remedial actions described above. It is expected that these remedial actions will be completed by the end of the second quarter of our 2007 fiscal year.

Table of Contents

PART II - OTHER INFORMATION

Item 6. Exhibits

Exhibits

- 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended.
- 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended.
- 32.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 14, 2007

HAPC, INC.

By: /s/ Erin S. Enright
Name: Erin S. Enright
Title Chief Financial Officer